Clinical
Trials
If you are a patient or health care provider who would like more information about a clinical trial, please contact our research team.
If you are a patient or health care provider who would like more information about a clinical trial, please contact our research team.
- Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized ParticipantsCondition:Covid-19 Infection and Pulmonary DistressMolecule:Zanubrutinib
- Study of Platinum Plus Etoposide With or Without Tislelizumab (BGB-A317) in Patients With Untreated Extensive-Stage Small Cell Lung CancerCondition:Lung CancerMolecule:Tislelizumab
- Study of Tislelizumab (BGB-A317) Versus Placebo in Combination With Chemoradiotherapy in Patient With ESCCCondition:Esophageal CancerMolecule:Tislelizumab
- Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Patients With Urothelial CarcinomaCondition:Bladder CancerMolecule:Tislelizumab
- Study of Tislelizumab (BGB-A317) in Patients With Locally Advanced or Metastatic Urothelial Bladder CancerCondition:Bladder CancerMolecule:Tislelizumab
- A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's LymphomaCondition:LymphomaMolecule:Zanubrutinib
- Study of the Safety and Pharmacokinetics of Lifirafenib (BGB-283) and PD-0325901 in Patients With Advanced or Refractory Solid TumorsCondition:Advanced solid tumorsMolecule:Lifirafenib
- A Study Tislelizumab (BGB A317) Combined With Gemcitabine Plus Cisplatin Versus Placebo Combined With Gemcitabine Plus Cisplatin in Recurrent or Metastatic Nasopharyngeal CancerCondition:Nasopharyngeal CancerMolecule:Tislelizumab
- A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Patients With Unresectable Locally Advanced or Metastatic HCC or GC/GEJCCondition:Gastric Cancer, Hepatocellular CarcinomaMolecule:Sitravatinib + Tislelizumab
- Study of Zanubrutinib in Patients With Marginal Zone LymphomaCondition:LymphomaMolecule:Zanubrutinib
See All Trials
Clinical trials are an important part of our research and development efforts and help make possible access to safe and potentially life-saving treatments.